Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Debra Patt, MD, PhD, MBA, executive vice president of policy and strategic initiatives and director of public policy at Texas Oncology, joins hosts Emeline Aviki, MB, MBA, medical director and attending surgeon at NYU Langone Perlmutter Cancer Center, and Stephen, MD, MBA, chief medical officer at Tennessee Oncology, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Patt is a policy and physician expert, breast cancer specialist, and board member of the Community Oncology Alliance and American Society of Clinical Oncology. Her in-depth conversation with Aviki and Schleicher addresses several important issues currently affecting high-quality oncology care: most important, the current drug shortage, and the economics that made it a problem, innovative ways to fix it, and economic solutions to prevent it from perpetuating.
They also discuss the instability of drug pricing—wholesale acquisition cost vs average sales price—the relationship between cancer and aging, pharmacy benefits managers and how they have affected the price of cancer care, and facilitating meaningful change for patients.
For audio only:
Listen above or on one of these podcast services:
New AI Tool Identifies Undiagnosed PNH in Health Records
October 30th 2024The machine learning model shows promise in detecting paroxysmal nocturnal hemoglobinuria (PNH) by assessing electronic health records (EHR) data, potentially transforming the diagnostic landscape for rare diseases.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen